A NEW FRONTIER
Tune Therapeutics is pioneering the next generation of genetic therapies.
Historically, genetic medicine has focused almost exclusively on changes within protein-coding genes. Yet only a fraction of the genetics associated with disease involves changes of this type.
The vast majority of human disease is the result of changes in gene expression, driven by epigenomic regulators that determine cell state and fate.
By exploring this new landscape of epigenomic control, we are discovering novel targets that are invisible or inaccessible to other approaches.
Genetic tuning enables us to control expression levels across multiple genes simultaneously, by affecting the packing and accessibility of cellular DNA.
OUR APPROACH
Unlike genome editing, our proprietary TEMPO platform dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once (multiplexing). This allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging.
Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.
OUR TEAM
Tune is driven by leaders with deep expertise in the fields of gene and cell therapy, genome editing, and epigenetics. In breaking free from the limitations of traditional genetic medicine, we are developing solutions for even the most challenging and intractable diseases – and building the capacity to transform human health and medicine.
Matt Kane
Chief Executive Officer
READ BIO
Akira Matsuno
Co-Founder, President and Chief Financial Officer
READ BIO
Charles A. Gersbach, Ph.D.
Co-Founder, Acting Chief Scientific Officer
READ BIO
Heidi Zhang, Ph.D.
Executive Vice President, Technical Operations
READ BIO
Blythe Sather, Ph.D.
Vice President, Head of Research
READ BIO
Fyodor Urnov, Ph.D.
Co-Founder, Scientific Advisory Board
READ BIO
Matt Kane
Chief Executive Officer
READ BIO
Charles A. Gersbach, Ph.D.
Co-Founder, Acting Chief Scientific Officer
READ BIO
Ali Behbahani, M.D.
New Enterprise Associates
READ BIO
Dan McHugh
Emerson Collective
READ BIO
NEWS
12/02/2021
Tune Therapeutics Launches with Pioneering Epigenomic Control Platform to Master Gene Networks, Treat Broad Range of Diseases
READ MOREOPENINGS
Click position title to learn more. Email careers@tunetx.com to apply.
We are looking for the Head of Quality who will establish and ensure compliance with Quality requirements, global regulatory and industry standards, internal standard operating procedures (SOPs), and federal regulations.
